Regeneron, R3767-ONC-2466, Ph2, open label, Melanoma, Fianlimab Plus Cemiplimab

What is the Purpose of this Study?

Primary -Assess Overall Survival (OS) of patients with melanoma treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613 Secondary -Assess Progression-Free Survival (PFS) -Assess Objective Response Rate (ORR) -Assess Duration of Response (DOR) -Assess Disease Control Rate (DCR) and CR -Assess long-term safety -Concomitant medications


Eligibility


Where can I participate?

CS Cancer at The Angeles Clinic and Research Institute : Marquis Keene, Saba Mukarram

More about this Clinical Trial

What is the full name of this clinical trial?

Extended Follow-up of Patients with Melanoma Treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from Study R3767-ONC-1613

Study Details
Disease Type/Condition

Melanoma

Principal Investigator

Hamid, Omid

Co-Investigators

Cathie T Chung, Inderjit Mehmi, Iryna Singh, Justin Moyers, Kristopher Wentzel, Navid Hafez, Vi K. Chiu

Age Group

Adult

Phase

II

IRB Number

STUDY00004022

ClinicalTrials.gov ID

NCT00129356

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Melanoma

Principal Investigator

Hamid, Omid

Age Group

Adult

Phase

II

IRB Number

R3767-ONC-2466

ClinicalTrials.gov ID

NCT00129356

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org